Cellectis SA (US:CLLS) — Company Overview, News & Financial Data
Cellectis is a biopharmaceutical company focused on immunotherapies using gene-edited T-cells to target cancer.
Cellectis SA
Cellectis (EPA:ALCLS), (NASDAQ:CLLS) is a biopharmaceutical company focused on developing immunotherapies based on gene-edited T-cells, using its pioneering TALEN technology and CRISPR-Cas9. The company is headquartered in Paris, France, and operates globally, aiming to harness the power of the immune system to target and eradicate cancers. Cellectis is also known for its innovative approach in the field of gene editing, endeavoring to create more effective and safer therapies for patients worldwide. Its project portfolio includes multiple pre-clinical and clinical trials, focusing primarily on CAR-T cell therapies, a groundbreaking approach in cancer treatment. Cellectis is driven by the objective to make accessible life-saving UCART product candidates to address unmet needs in the treatment of multiple aggressive cancers.
Snapshot
Operations
Products and/or services of Cellectis SA
- UCART19, an engineered T-cell product targeting CD19-expressing malignancies.
- ALLO-501, aimed at treating non-Hodgkin lymphoma through modified T-cells.
- TALLEN, a gene-editing technology for precision genome modifications.
- UCART123, developed for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
- UCART22, designed for B-cell acute lymphoblastic leukemia therapy.
- BALLI-01 trial, assessing the safety and efficacy of UCART22 in B-ALL patients.
Cellectis SA executive team
- Dr. Andre Choulika Ph.D.Co-Founder, CEO & Director
- Dr. David J. Sourdive Ph.D.Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director
- Mr. Arthur StrilCFO & Chief Business Officer
- Valerie CrosPrincipal Financial Officer & Principal Accounting Officer
- Mr. Jean Charles Epinat Ph.D.Chief Technological Officer
- Dr. Philippe Duchateau Ph.D.Chief Scientific Officer
- Ms. Marie-Bleuenn TerrierGeneral Counsel & Secretary of the Board of Directors
- Pascalyne WilsonDirector of Communications
- Ms. Kyung Nam-WortmanExecutive VP & Chief Human Resources Officer
- Mr. Stephan Reynier M.Sc.Chief Regulatory & Pharmaceutical Compliance Officer